JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Khaw, B.-A.
Right arrow Articles by Johnson, L. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Khaw, B.-A.
Right arrow Articles by Johnson, L. L.
Journal of Nuclear Medicine Vol. 47 No. 5 868-876
© 2006 by Society of Nuclear Medicine


Basic Science Investigation

Imaging Experimental Atherosclerotic Lesions in ApoE Knockout Mice: Enhanced Targeting with Z2D3-Anti-DTPA Bispecific Antibody and 99mTc-Labeled Negatively Charged Polymers

Ban-An Khaw1, Yared Tekabe1,2 and Lynne L. Johnson2

1 Center for Cardiovascular Targeting, School of Pharmacy, Bouve College of Health Sciences, Northeastern University, Boston, Massachusetts; and 2 Division of Cardiology, Department of Medicine, Columbia University Medical Center, New York, New York

Correspondence: For correspondence or reprints contact: Ban-An Khaw, PhD, Center for Cardiovascular Targeting, School of Pharmacy, Bouve College of Health Sciences, Northeastern University, Boston, MA 02115 E-mail: b.khaw{at}neu.edu

In vivo molecular imaging may be improved if specific radioactivity at the target site could be increased while maintaining low background activity. Bispecific antibody complexes and 99mTc-labeled negatively charged chelating polymers that react specifically with the capture arm of the bispecific antibody complex were used to demonstrate the feasibility of imaging very small atherosclerotic lesions in ApoE knockout mice. Methods: Left femoral artery denudation in ApoE–/– mice on a hyperlipidemic diet was used to induce accelerated atherosclerotic lesions. Approximately 40 µg of bispecific antibodies were injected intravenously after 2 wk of endothelial denudation. The next day, ~15.0 MBq 99mTc-DTPA–succinyl-polylysine (2 µg; DTPA is diethylenetriaminepentaacetic acid) were injected intravenously. Results: In vivo {gamma}-images showed that lesions were observed unequivocally by 2–3 h. Sham-operated right femoral regions showed no radiotracer accumulation. Ex vivo {gamma}-scintillation counting corrected for sham-operated nonspecific activity and lesion mass showed that the mean lesion activity was 10.10 ± 6.76 %ID/g (percentage injected dose per gram), whereas nonspecific human IgG bispecific control (NSB control) also corrected similarly was 0.939 ± 0.877 %ID/g (P < 0.03). Atherosclerotic lesions were confirmed by immunohistochemical staining. Computer planimetry of immunohistograms showed the mean lesion size to be 2.64 ± 2.46 mg. Conclusion: Use of bispecific antibody complexes and 99mTc-DTPA–succinyl-polylysine enabled in vivo visualization of very small atherosclerotic lesions in ApoE knockout mice.

Key Words: bispecific antibody • pretargeting • radiolabeled polymer







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2006 by the Society of Nuclear Medicine.